1 Section of Infection and Immunity, University of Wales College of Medicine, Tenovus Building, Heath Park, Cardiff CF14 4XX, UK
2 MRC Virology Unit, Institute of Virology, Church Street, Glasgow G11 5JR, UK
3 Dstl Chemical and Biological Sciences, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK
Correspondence
Gavin W. G. Wilkinson
WilkinsonGW1{at}cf.ac.uk
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() |
---|
The GenBank/EMBL/DDBJ accession number for the HAdV-4 genome reported in this paper is AY487947.
![]() |
MAIN TEXT |
---|
![]() ![]() ![]() ![]() |
---|
Vaccine strains have obvious potential as vehicles for delivery and expression of foreign antigens. Replication-competent HAdV-4 and HAdV-7 recombinants that encode human immunodeficiency virus or hepatitis B virus envelope proteins have been evaluated in animal models and limited human trials (Lubeck et al., 1989, 1994
; Mason et al., 1990
; Chengalvala et al., 1991
, 1994
, 1997
; Tacket et al., 1992
; Patterson et al., 2002
). Encouraging results were obtained following oral administration in chimpanzees and humans. Safety indices were high, active virus replication was observed, immune responses were generated against the vector and transgene and there was evidence of enhanced responses following sequential delivery of different serotypes.
HAdV-4 and four simian viruses (SAdV-22SAdV-25) comprise HAdV-E, one of the six species (HAdV-AHAdV-F) that encompass primate adenoviruses (Benk et al., 2000
). HAdV-4 strains can be differentiated into two groups on the basis of minor differences in restriction endonuclease digest patterns; the prototype strain [RI-67, deposited in the American Type Culture Collection (ATCC) as VR-4] and vaccine strain (CL 68578) are members of the same group (Li & Wadell, 1988
). DNA sequence data are available for several loci in a variety of HAdV-4 strains (Tokunaga et al., 1982
, 1986
; Hay, 1985
; Kitchingman, 1985
; Gruber et al., 1993
; Kidd et al., 1995
; Pring-Åkerblom et al., 1995
; Crawford-Miksza et al., 1999
; Tarassishin et al., 1999
; Li & Wold, 2000
). Here, we report the complete DNA sequence of the vaccine strain, thus defining a therapeutic agent and enabling researchers to access a genome sequence for at least one human adenovirus from each of the six species. We also describe a system for construction of replication-competent HAdV-4 recombinants.
HAdV-4 strain CL 68578 was cultured directly from the vaccine, strain RI-6 was kindly supplied by Professor R. T. Hay (University of St Andrews, UK) and strain VR-4 was obtained from the ATCC. These viruses were propagated and titrated in the cell line A549 (ECACC). Virus particles were purified from infected cells by extraction with Arklone P and CsCl gradient centrifugation (Scarpini et al., 1999) and then treated with RNase A. Virion DNA was purified by using a QIAamp DNA Blood kit (Qiagen) and sequenced directly by using customized primers that were based initially on published sequences. By using an ABI 377 instrument, both DNA strands were sequenced except for the terminal 300 bp sections, which were sequenced only in the direction towards the termini. Sequences were aligned and compiled by using the Lasergene programs (DNASTAR) and analysed by using the GCG programs (Accelrys), CLUSTALW (Thompson et al., 1994
) and PTRANS (Taylor, 1986
).
The genome of the HAdV-4 vaccine strain is 35 994 bp in length and has a G+C content of 57·7 mol%. It is thus marginally larger than the genomes of other characterized human adenoviruses and smaller than that of the chimpanzee adenovirus SAdV-25 (36 519 bp), which is the closest relative of HAdV-4. Analysis of the HAdV-4 sequence revealed that its genetic content is similar to that of other human adenoviruses (Fig. 1a). Comparisons with published data for various HAdV-4 genes indicated very few differences, most of which can be attributed to strain variation and the remainder to previous errors. Differences between the published sequences of the inverted terminal repeat (ITR) for strains RI-6 and VR-4 were confirmed independently (Table 1
). The corresponding vaccine strain sequence is identical to that of RI-6. The two sequences that are available for the SAdV-25 ITR also differ (Table 1
).
|
|
Comparative aspects of the E3 region in human adenovirus species have been summarized by Davison et al. (2003a). The E3 region contains three genes (RID-
, RID-
and 14.7K) at its 3' end and, in all but HAdV-F, a single gene (12.5K) at its 5' end. Several glycoprotein genes are located in between; the numbers range from two in HAdV-A to five in HAdV-E. Many of the proteins that are encoded by these genes are related to each other via a loosely conserved immunoglobulin-like domain (CR1), although it appears that this domain has been lost in some instances. SAdV-25 contains four CR1 genes, whereas HAdV-4 contains three, i.e. it lacks a counterpart to CR1-
1. A small, unrelated gene was assigned previously to the 328 bp sequence between HAdV-4 CR1-
1 and CR1-
1 (Li & Wold, 2000
; Burgert et al., 2002
). This assignment is unlikely to be correct, however, as it is clear that an alternative reading frame contains a 5'-truncated version of CR1-
1 that represents a deletion relative to SAdV-25 (Fig. 1a
). This vestigial element is unlikely to be expressed, as it lacks an initiating ATG and splice acceptor site. Like CR1-
1, it has diverged significantly from the corresponding region of its SAdV-25 counterpart. The deletion in CR1-
1 is not restricted to the vaccine strain, as it is also a feature of other strains, including VR-4 (Li & Wadell, 1988
; Li & Wold, 2000
; Burgert et al., 2002
). Rapid evolution of CR1 genes is evident in human adenoviruses from their variation in copy number and sequence; this evolution is seen here in the striking divergence of CR1-
1 (and probably CR1-
1 prior to the deletion event) and the loss of CR1-
1 function from HAdV-4. The CR1 family is likely to be involved in aspects of immune modulation, as is the case for other E3 genes.
Most genes in HAdV-4 and SAdV-25 exhibit highest similarity to those of HAdV-B (Kitchingman, 1985; Tokunaga et al., 1986
; Gruber et al., 1993
; Kidd et al., 1995
; Pring-Åkerblom & Adrian, 1995
). However, Gruber et al. (1993)
observed that HAdV-4 was related most closely to HAdV-C in the fibre gene. This prompted the suggestion that HAdV-4 evolution may have involved recombination between ancestors of HAdV-B and HAdV-C. Our analysis (not shown) supported a closer relationship between HAdV-4 and HAdV-C for this gene. However, all other genes have a closer relationship to HAdV-B, although a few (including those that are immediately adjacent to the fibre gene) are too small to permit convincing discrimination. It is possible, therefore, that the proposed recombination event involved only the fibre gene as a major determinant of tropism.
Characterization of the HAdV-4 sequence facilitated the generation of replication-competent recombinants. A transfer plasmid (pAL605) was constructed to permit insertion of exogenous sequences at a site between the E4 promoter and the ITR, a region where disruptions were considered unlikely to be deleterious to virus growth. Briefly, to generate pAL605, a synthetic HAdV-4 DNA duplex, extending from the SalI site at nt 35 855 to the right genome terminus (nt 35 994), was subcloned into vector pSP70 (Promega) by using HindIIIEcoRI linkers. A HAdV-4 BclISalI fragment (nt 31 45935 855) was inserted at the SalI site to generate pAL422, which thus contains an insert that corresponds to nt 31 45935 994. Next, the enhanced green fluorescent protein (EGFP) gene, under the control of an internal ribosomal entry site (IRES), was excised from pIRES2EGFP (Clontech) and flanked with loxP sites; the resulting construct was placed under the control of the human cytomegalovirus (HCMV) major immediateearly promoter (IEP; residues 299 to +69; Jacobs et al., 1992; Wilkinson & Akrigg, 1992
) and this was inserted into the unique SalI site in pAL422 to generate pAL605. The expression cassette thus comprised HAdV-4 (nt 31 45935 855)HCMV IEPloxPIRESEGFPloxPHAdV-4 (nt 35 856terminus). The unique BamHI site between the HCMV IEP and loxP site is available for transgene insertion (Fig. 2
a).
|
Generation of RAd605 demonstrated that the EGFP gene could be used as a selectable marker for the production of HAdV-4 recombinants. However, the EGFP gene was flanked by loxP sites in the transfer vector so that it could be excised specifically from HAdV-4 recombinants, leaving a transgene under the control of the HCMV IEP. The IRES and EGFP gene were removed by treating 1 µg RAd605 DNA with 1 U Cre recombinase (Novagen) at 37 °C for 1 h. The enzyme was inactivated by heating to 70 °C for 5 min and the reaction product was transfected into A549 cells. Non-fluorescent virus (RAd605EGFP) occurred at a frequency of 0·5 and was subjected to three rounds of plaque purification. Viral DNA was analysed by restriction endonuclease analysis and DNA sequencing (not shown). RAd605
EGFP contains the HCMV IEP and a polyadenylation signal, but no EGFP gene.
To investigate whether transgene insertion affected the in vitro growth properties of the HAdV-4 recombinants, A549 cells grown in a 25 cm2 tissue-culture flask were infected at an m.o.i. of 0·1 for 4 h with the Ad4 vaccine strain, RAd605 or RAd605EGFP. Both cells and supernatant were harvested at a range of times post-infection and subjected to three rounds of freezethawing. The supernatant was clarified by low-speed centrifugation, aliquotted and stored at 70 °C; titres were determined subsequently by plaque assay. Growth kinetics of the HAdV-4 vaccine strain, RAd605 and RAd605
EGFP were similar (Fig. 2c
), a result that is consistent with the theory that insertion at this locus is compatible with efficient HAdV-4 replication in vitro.
Successful experience with the HAdV-4 vaccine and generation of recombinants derived therefrom provide a solid basis for the development of replication-competent HAdV-4 vectors for use as vaccine carriers or in gene therapy. Although the EGFP gene is a useful marker, its inclusion would reduce the size capacity for additional transgenes. However, an alternative strategy is feasible, which would utilize the loss of EGFP expression from RAd605 by cotransfection with a transfer plasmid that contains an alternative transgene in place of the EGFP gene. This approach has been used to generate a replication-competent HAdV-4 recombinant that encodes the Venezuelan equine encephalitis virus glycoprotein complex E3E26K (not shown). Larger transgenes could be accommodated by the deletion of sequences elsewhere in the genome, but this is likely to alter virus viability and antigen presentation in vivo (Tacket et al., 1992; Chengalvala et al., 1997
; Patterson et al., 2002
).
![]() |
ACKNOWLEDGEMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() |
---|
Benk, M., Harrach, B. & Russell, W. C. (2000). Family Adenoviridae. In Virus Taxonomy: Seventh Report of the International Committee on Taxonomy of Viruses, pp. 227238. Edited by M. H. V. van Regenmortel, C. M. Fauquet, D. H. L. Bishop, E. B. Carstens, M. K. Estes, S. M. Lemon, J. Maniloff, M. A. Mayo, D. J. McGeoch, C. R. Pringle & R. B. Wickner. San Diego: Academic Press.
Burgert, H. G., Ruzsics, Z., Obermeier, S., Hilgendorf, A., Windheim, M. & Elsing, A. (2002). Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 269, 273318.[Medline]
Chanock, R. M., Ludwig, W., Heubner, R. J., Cate, T. R. & Chu, L. W. (1966). Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA 195, 445452.[CrossRef][Medline]
Chengalvala, M., Lubeck, M. D., Davis, A. R., Mizutani, S., Molnar-Kimber, K., Morin, J. & Hung, P. P. (1991). Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine 9, 485490.[CrossRef][Medline]
Chengalvala, M. V., Bhat, B. M., Bhat, R., Lubeck, M. D., Mizutani, S., Davis, A. R. & Hung, P. P. (1994). Immunogenicity of high expression adenovirushepatitis B virus recombinant vaccines in dogs. J Gen Virol 75, 125131.[Abstract]
Chengalvala, M. V., Bhat, B. M., Bhat, R. A., Dheer, S. K., Lubeck, M. D., Purcell, R. H. & Murthy, K. K. (1997). Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine 15, 335339.[CrossRef][Medline]
Crawford-Miksza, L. K. & Schnurr, D. P. (1996). Adenovirus serotype evolution is driven by illegitimate recombination in the hypervariable regions of the hexon protein. Virology 224, 357367.[CrossRef][Medline]
Crawford-Miksza, L. K., Nang, R. N. & Schnurr, D. P. (1999). Strain variation in adenovirus serotypes 4 and 7a causing acute respiratory disease. J Clin Microbiol 37, 11071112.
Davison, A. J., Akter, P., Cunningham, C. & 7 other authors (2003a). Homology between the human cytomegalovirus RL11 gene family and human adenovirus E3 genes. J Gen Virol 84, 657663.
Davison, A. J., Benk, M. & Harrach, B. (2003b). Genetic content and evolution of adenoviruses. J Gen Virol 84, 28952908.
Farina, S. F., Gao, G., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C. J. & Wilson, J. M. (2001). Replication-defective vector based on a chimpanzee adenovirus. J Virol 75, 1160311613.
Gruber, W. C., Russell, D. J. & Tibbetts, C. (1993). Fiber gene and genomic origin of human adenovirus type 4. Virology 196, 603611.[CrossRef][Medline]
Hay, R. T. (1985). Origin of adenovirus DNA replication. Role of the nuclear factor I binding site in vivo. J Mol Biol 186, 129136.[Medline]
Hilleman, M. R. & Werner, J. H. (1954). Recovery of new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 85, 183188.
Jacobs, S. C., Stephenson, J. R. & Wilkinson, G. W. G. (1992). High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol 66, 20862095.[Abstract]
Kidd, A. H., Garwicz, D. & Öberg, M. (1995). Human and simian adenoviruses: phylogenetic inferences from analysis of VA RNA genes. Virology 207, 3245.[CrossRef][Medline]
Kitchingman, G. R. (1985). Sequence of the DNA-binding protein of a human subgroup E adenovirus (type 4): comparisons with subgroup A (type 12), subgroup B (type 7), and subgroup C (type 5). Virology 146, 90101.[CrossRef][Medline]
Li, Q.-G. & Wadell, G. (1988). The degree of genetic variability among adenovirus type 4 strains isolated from man and chimpanzee. Arch Virol 101, 6577.[Medline]
Li, Y. & Wold, W. S. M. (2000). Identification and characterization of a 30K protein (Ad4E3-30K) encoded by the E3 region of human adenovirus type 4. Virology 273, 127138.[CrossRef][Medline]
Lubeck, M. D., Davis, A. R., Chengalvala, M. & 8 other authors (1989). Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 86, 67636767.[Abstract]
Lubeck, M. D., Natuk, R. J., Chengalvala, M. & 12 other authors (1994). Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retrovir 10, 14431449.[Medline]
Mason, B. B., Davis, A. R., Bhat, B. M. & 9 other authors (1990). Adenovirus vaccine vectors expressing hepatitis B surface antigen: importance of regulatory elements in the adenovirus major late intron. Virology 177, 452461.[CrossRef][Medline]
McNeill, K. M., Hendrix, R. M., Lindner, J. L., Benton, F. R., Monteith, S. C., Tuchscherer, M. A., Gray, G. C. & Gaydos, J. C. (1999). Large, persistent epidemic of adenovirus type 4-associated acute respiratory disease in U.S. army trainees. Emerg Infect Dis 5, 798801.[Medline]
Patterson, L. J., Prince, G. A., Richardson, E., Alvord, W. G., Kalyan, N. & Robert-Guroff, M. (2002). Insertion of HIV-1 genes into Ad4E3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 292, 107113.[CrossRef][Medline]
Pring-Åkerblom, P. & Adrian, T. (1995). Sequence characterization of the adenovirus 31 fibre and comparison with serotypes of subgenera A to F. Res Virol 146, 343354.[CrossRef][Medline]
Pring-Åkerblom, P., Trijssenaar, F. E. J. & Adrian, T. (1995). Sequence characterization and comparison of human adenovirus subgenus B and E hexons. Virology 212, 232236.[CrossRef][Medline]
Rubin, B. A. & Rorke, L. B. (1994). Adenovirus vaccines. In Vaccines, 2nd edn, pp. 475502. Edited by S. A. Plotkin & E. A. Mortimer. Philadelphia, PA: W. B. Saunders.
Scarpini, C., Arthur, J., Efstathiou, S., McGrath, Y. & Wilkinson, G. (1999). Herpes simplex virus and adenovirus vectors. In DNA Viruses: A Practical Approach, pp. 267306. Edited by A. J. Cann. Oxford: Oxford University Press.
Tacket, C. O., Losonsky, G., Lubeck, M. D., Davis, A. R., Mizutani, S., Horwith, G., Hung, P., Edelman, R. & Levine, M. M. (1992). Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 10, 673676.[CrossRef][Medline]
Tarassishin, L., Szawlowski, P., McLay, J., Kidd, A. H. & Russell, W. C. (1999). Adenovirus core protein VII displays a linear epitope conserved in a range of human adenoviruses. J Gen Virol 80, 4750.[Abstract]
Taylor, P. (1986). A computer program for translating DNA sequences into protein. Nucleic Acids Res 14, 437441.[Abstract]
Thompson, J. D., Higgins, D. G. & Gibson, T. J. (1994). CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22, 46734680.[Abstract]
Tokunaga, O., Shinagawa, M. & Padmanabhan, R. (1982). Physical mapping of the genome and sequence analysis at the inverted terminal repetition of adenovirus type 4 DNA. Gene 18, 329334.[CrossRef][Medline]
Tokunaga, O., Yaegashi, T., Lowe, J., Dobbs, L. & Padmanabhan, R. (1986). Sequence analysis in the E1 region of adenovirus type 4 DNA. Virology 155, 418433.[CrossRef][Medline]
Wilkinson, G. W. G. & Akrigg, A. (1992). Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucleic Acids Res 20, 22332239.[Abstract]
Received 21 June 2004;
accepted 15 July 2004.